General Information of Drug (ID: DMRSOBG)

Drug Name
Mdl 101,146 Drug Info
Synonyms
UNII-2D08A509S3; CHEBI:45517; CHEMBL56852; 1-{3-METHYL-2-[4-(MORPHOLINE-4-CARBONYL)-BENZOYLAMINO]-BUTYRYL}-PYRROLIDINE-2-CARBOXYLIC ACID (3,3,4,4,4-PENTAFLUORO-1-ISOPROPYL-2-OXO-BUTYL)-AMIDE; 2D08A509S3; Mdl 101,146; N-[4-(morpholin-4-ylcarbonyl)benzoyl]-L-valyl-N-[(3S)-5,5,6,6,6-pentafluoro-2-methyl-4-oxohexan-3-yl]-L-prolinamide; N-{[4-(morpholin-4-ylcarbonyl)phenyl]carbonyl}-L-valyl-N-[(1S)-3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]-L-prolinamide; MDL-101146, (S)-; AC1NRD4J; BDBM50058341; 163660-59-1
Indication
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Terminated [1]
Cross-matching ID
PubChem CID
46936357
CAS Number
CAS 149859-17-6
TTD Drug ID
DMRSOBG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alpha 1-PI DMXC1K9 Alpha-1 antitrypsin deficiency 5C5A Approved [3]
Erdosteine DM6QFSV Bronchitis CA20 Approved [4]
Sivelestat DM6BZCV Crohn disease DD70 Phase 3 [5]
WIN-63759 DMRV48P Emphysema CA21 Terminated [6]
SSR-69071 DMWL4MI Chronic obstructive pulmonary disease CA22 Terminated [7]
SYN-1134 DMG2SQM Cystic fibrosis CA25 Terminated [8]
PBI-1101 DMWD1RC Inflammation 1A00-CA43.1 Terminated [9]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [2]
Grassystatin a DM1PWX2 Discovery agent N.A. Investigative [10]
Dimethylformamide DML6O4N Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Neutrophil elastase (NE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sivelestat sodium hydrate DMOSJD0 Acute lung injury NB32.3 Phase 4 [12]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [13]
Sivelestat DM6BZCV Crohn disease DD70 Phase 3 [14]
Tiprelestat DM1SB94 Myocardial infarction BA41-BA43 Phase 2 [15]
AZD9668 DMB87M3 Bronchiectasis CA24 Phase 2 [16]
L-694,458 DMA0DSJ Cystic fibrosis CA25 Phase 2 [17]
BAY 85-8501 DMCPUKG Bronchiectasis CA24 Phase 2 [18]
DX-890 DMBFZET Acute lung injury NB32.3 Phase 2 [12]
POL-6014 DM9B68S Cystic fibrosis CA25 Phase 1 [19]
AZD-9819 DMWYHXG Chronic obstructive pulmonary disease CA22 Phase 1 [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neutrophil elastase (NE) TTPLTSQ ELNE_HUMAN Inhibitor [2]
Pancreatic elastase 1 (CELA1) TT3NKIB CELA1_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007771)
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 Elastase inhibitors. J Soc Biol. 2001;195(2):143-50.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8.
6 Biological activity of WIN 63759, an orally bioavailable inhibitor of human neutrophil elastase. Drug Development Research Volume 34, Issue 3, pages 306-316, March 1995.
7 Pivotal role for alpha1-antichymotrypsin in skin repair. J Biol Chem. 2011 Aug 19;286(33):28889-901.
8 EP patent application no. 1292314, Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans.
9 CN patent application no. 1813706, Use of elastic protease inhibitor for preparing medicine for protecting cerebral hemorrhage.
10 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
11 Liver disease associated with occupational exposure to the solvent dimethylformamide. Ann Intern Med. 1988 May;108(5):680-6.
12 Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.
13 Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5.
14 Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.
15 Company report (Proteo Biotech AG)
16 Clinical pipeline report, company report or official report of AstraZeneca (2009).
17 Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
18 Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73.
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358).
20 Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9.